Because loss of lncRNA-ANRIL can effectively attenuate the effects of AMPK activation, both AMPK and lncRNA-ANRIL might be a therapeutic target on the prevention of atherosclerosis-associated vascular diseases, such as stroke. This evidence concerns the gene CDKN2B-AS1 and atherosclerosis.